Prediction of Esophageal and Lung Toxicities After Radiation (Chemo) Therapy

University Hospital, Brest167 enrolled

Overview

(Chemo)-radiotherapy is the gold standard therapeutic treatment for patients with locally advanced lung cancer non accessible or ineligible for surgery. While some progress occurred regarding progression free survival and overall survival thanks to recent advances (i.e., durvalumab), prediction of pulmonary and esophageal toxicity, remains insufficiently accurate. Current dose-volume histograms (DVH) do not account for spatial dose distribution and strict application of current dose constraints does not prevent toxicity events in some of the treated patients. The goal of this work was to investigate the added predictive value of the radiomics approach applied to dose maps regarding acute and late toxicity in both lungs and the esophagus.

Study Type

OBSERVATIONAL

Enrollment

167

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients treated by (chemo)-radiotherapy for a primary lung cancer by radiotherapy Exclusion Criteria: * Incomplete treatment

Locations (1)

CHRU Brest

Brest, Finistère, France

Outcomes

Primary Outcomes

Prediction of Acute Pulmonary Toxicity

The model's performance will be evaluated based on the observed rate of Acute Pulmonary Toxicity using classification metrics (area Under the curve, balanced accuracy).

Time frame: Up to 6 months

Prediction of Late Pulmonary Toxicity

The model's performance will be evaluated based on the observed rate of Late Pulmonary Toxicity using classification metrics (area Under the curve, balanced accuracy).

Time frame: Between 6 months and 2 years after radiotherapy

Prediction of Acute Oesophageal Toxicity

The model's performance will be evaluated based on the observed rate of Acute Oesophageal Toxicity using classification metrics (area Under the curve, balanced accuracy).

Time frame: Up to 6 months

Prediction of Late Oesophageal Toxicity

The model's performance will be evaluated based on the observed rate of Late Oesophageal Toxicity using classification metrics (area Under the curve, balanced accuracy).

Time frame: Between 6 months and 2 years after radiotherapy